Inventor · disambiguated record
Joost Oppenheim
Also filed as: OPPENHEIM JOOST · OPPENHEIM JOOST J
12 granted patents·10 pending applications·121 citations·filing 1988–2018
90Inventor score
Top patents by PatentIndex Score
22 records- 0190US5698196AAntibodies specific for neutrophic chemotactic factorUS HEALTH·Filed 1995·Granted Dec 16, 1997·58 cites·11 claims
- 0286US8227417B2HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressantsYANG DE·Filed 2009·Granted Jul 24, 2012·9 cites·32 claims
- 0378US6808877B2Ligands for FPR class receptors that induce a host immune response to a pathogen or inhibit HIV infectionUS HEALTH·Filed 2002·Granted Oct 26, 2004·11 cites·9 claims
- 0470US5652338ANeutrophil chemotactic factorUS HEALTH·Filed 1988·Granted Jul 29, 1997·15 cites·1 claims
- 0568US5925352AMethod of treating inflammation with antibodies to neutrophil chemotactic factorUS HEALTH·Filed 1997·Granted Jul 20, 1999·12 cites·2 claims
- 0663US6830893B2T20/DP178 is an activator of human phagocyte formyl peptide receptorsUS HEALTH·Filed 2001·Granted Dec 14, 2004·2 cites·5 claims
- 0760US6475741B1Neutrophil chemotactic factor cloned cDNA and monoclonal antibodies theretoUS HEALTH·Filed 2001·Granted Nov 5, 2002·0 cites·2 claims
- 0859US11389480B2Human monoclonal antibody targeting TNFR2 for cancer immunotherapyUS HEALTH·Filed 2018·Granted Jul 19, 2022·0 cites·41 claims
- 0959US9567566B2HMGN polypeptides as immune enhancers and HMGN antagonists as immune suppressantsYANG DE·Filed 2012·Granted Feb 14, 2017·0 cites·13 claims
- 1056US6376659B1Nucleic acids encoding a novel neutrophil chemotactic factorNASA·Filed 1997·Granted Apr 23, 2002·11 cites·6 claims
- 1153US11266746B2Therapeutic antitumor combination of a TLR4 ligand with other treatmentsUS HEALTH·Filed 2017·Granted Mar 8, 2022·0 cites·24 claims
- 1253US2016296620A1Hmgn polypeptides as immune enhancers and hmgn antagonists as immune suppressantsTHE USA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES·Filed 2016·Application pending·0 cites
- 1350US2005085629A1Utilization of FPRL1 as a functional receptor by serum amyloid A (SAA)Filed 2004·Application pending·0 cites
- 1448US2002072495A1LL-37 is an immunostimulantFiled 2001·Application pending·0 cites
- 1546US2005130890A1Amyloid beta is a ligand for FPR class receptorsFiled 2004·Application pending·0 cites
- 1644US2004013679A1LL-37 is an immunostimulantFiled 2003·Application pending·0 cites
- 1743US2003120037A1Utilization of FPRL1 as a functional receptor by serum amyloid a (SAA)Filed 2002·Application pending·0 cites
- 1841US2006008891A1Cathepsin G-related peptides as modulators of formylpeptide receptors (FPR)GOVERNMENT OF USA AS REPERSENT·Filed 2005·Application pending·0 cites
- 1941US2003211105A1Methods for reducing tumor growth and metastasis by inhibiting mcp-1 activityFiled 2001·Application pending·0 cites
- 2039US2006008808A1Compositions and methods for enhancing an immune responseYANG DE·Filed 2004·Application pending·0 cites
- 2134US6562859B1Ureido derivatives of poly-4-amino-2-carboxy-1-methyl pyrrole compounds for inhibition of inflammationUS HEALTH·Filed 1998·Granted May 13, 2003·3 cites·23 claims
- 2233US2006116325A1Methods and compositions for inhibiting hiv-coreceptor interactionsCHERTOV OLEG·Filed 2002·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →